Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis

Company Overview

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Key Stats

• Today's Range: $26.54 to $28.32
• 50-Day Range: $18.65 to $30.33
• 52-Week Range: $17.38 to $30.69
• Volume: 907,293 shs
• Average Volume: 516,217 shs
• Market Capitalization: $2.07 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.80
• Consensus Rating: Buy

Kiniksa Pharmaceuticals Stock Analysis - MarketRank™

Kiniksa Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 389th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Kiniksa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kiniksa Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kiniksa Pharmaceuticals are expected to grow in the coming year, from ($0.55) to $0.25 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kiniksa Pharmaceuticals is -202.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kiniksa Pharmaceuticals is -202.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kiniksa Pharmaceuticals has a P/B Ratio of 4.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.29% of the float of Kiniksa Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Kiniksa Pharmaceuticals has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Kiniksa Pharmaceuticals has recently decreased by 17.82%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kiniksa Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Kiniksa Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.29% of the float of Kiniksa Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Kiniksa Pharmaceuticals has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Kiniksa Pharmaceuticals has recently decreased by 17.82%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.38

News Sentiment

Kiniksa Pharmaceuticals has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 21 news articles for Kiniksa Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

6 people have searched for KNSA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

3 people have added Kiniksa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Kiniksa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,081,708.00 in company stock.

Percentage Held by Insiders

53.48% of the stock of Kiniksa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

53.95% of the stock of Kiniksa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KNSA Stock Analysis - Frequently Asked Questions

How have KNSA shares performed this year?

Kiniksa Pharmaceuticals' stock was trading at $19.78 at the start of the year. Since then, KNSA shares have increased by 43.1% and is now trading at $28.30.
View the best growth stocks for 2025 here.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) released its quarterly earnings results on Tuesday, April, 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.09. The business's revenue for the quarter was up 72.5% on a year-over-year basis.
Read the conference call transcript.

When did Kiniksa Pharmaceuticals IPO?

Kiniksa Pharmaceuticals (KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' top institutional shareholders include Vanguard Group Inc. (4.62%), Braidwell LP (2.69%), Acadian Asset Management LLC (1.42%) and Millennium Management LLC (1.16%). Insiders that own company stock include Sanj K Patel, Eben Tessari, John F Paolini, Michael R Megna, Mark Ragosa, Barry D Quart and Ross Moat.
View institutional ownership trends.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kiniksa Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 4/29/2025
• Today: 6/14/2025
• Next Earnings (Estimated): 7/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KNSA
• CIK: 1730430
• Web: www.kiniksa.com
• Phone: (781) 431-9100
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $38.80
• High Stock Price Target: $45.00
• Low Stock Price Target: $34.00
• Potential Upside/Downside: +37.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $14.08 million
• Net Margins: -2.36%
• Pretax Margin: -4.35%
• Return on Equity: -7.31%
• Return on Assets: -5.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.24
• Quick Ratio: 2.95

Sales & Book Value

• Annual Sales: $481.17 million
• Price / Sales: 4.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.23 per share
• Price / Book: 4.54

Miscellaneous

• Outstanding Shares: 72,971,000
• Free Float: 32,801,000
• Market Cap: $2.07 billion
• Optionable: Optionable
• Beta: 0.06